$ENTX News
Last published 5d ago
- 5d agoENTXEntera Bio Ltd. - EXHIBIT 99.1Earnings ReleasesForm 8-K - Current report - Item 2.02 Item 7.01 Item 9.01
- 5d agoENTXEntera Announces Third Quarter 2026 Financial Results and Business UpdatesGlobeNewswireClinical Preparations Advanced for EB613 Phase 3 Osteoporosis Study, with First Site Activation Expected in Late 2026 Clinical and Commercial Leadership...
- 5d agoENTXEntera Announces Third Quarter 2026 Financial Results and Business UpdatesGlobeNewswireClinical Preparations Advanced for EB613 Phase 3 Osteoporosis Study, with First Site Activation Expected in Late 2026 Clinical and Commercial Leadership Expanded with Appointment of Senior Executives and Directors
- 2w agoENTXOGNMRKEntera Appoints Global Research and Development Leader Dr. Juan Camilo Arjona Ferreira to Its Board of DirectorsGlobeNewswireDr. Arjona Ferreira currently serves as Head of Research and Development and Chief Medical Officer at Organon & Co. (NYSE:OGN) He joins Entera with two decades of clinical development, regulatory execution, and
- 4w agoENTXEntera Presents Markedly Enhanced Anabolic Effects of EB613 (First-in-Class Oral PTH(1-34) Tablet) in Postmenopausal Women with Osteoporosis at High Risk of Fracture and Showcases Phase 3 Design at ASBMR 2026 Annual MeetingGlobeNewswirePost-hoc Phase 2 data show greater bone mineral density (BMD) gains and anabolic effect with EB613 in postmenopausal women with baseline T-scores of ≤-2.5 (osteoporosis) versus T-scores of >-2.5 (osteopenia) These
- 1mo agoENTXEntera Bio Announces Additional Presentation of EB613 Phase 3 Study Design at the ASBMR 2026 Annual MeetingGlobeNewswireTEL AVIV, Israel, Oct. 08, 2026 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ:ENTX) ("Entera" or the "Company"), a leader in the development of oral peptides, today announced that an additional
- 2mo agoENTXCorrection: Entera to Participate in Upcoming Fall Investor ConferencesGlobeNewswireTEL AVIV, Israel, Aug. 27, 2026 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ:ENTX) ("Entera" or the "Company"), a leader in the development of oral peptides, today announced that the Company’s Chief
- 2mo agoENTXEntera to Participate in Upcoming Fall Investor ConferencesGlobeNewswireTEL AVIV, Israel, Aug. 27, 2026 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ:ENTX) ("Entera" or the "Company"), a leader in the development of oral peptides, today announced that the Company’s Chief
- 2mo agoENTXEntera Appoints Global Pharmaceutical Leader Riccardo Paolo Camisasca, M.D., as Chief Medical Officer Ahead of Planned EB613 Phase 3 InitiationGlobeNewswireDr. Camisasca joins Entera with 30 years of global pharmaceutical research and clinical development experience including roles at Sumitomo Pharma, Takeda, and Novartis Appointment further strengthens Entera’s clinical
- 3mo agoENTXCG 46TH ANNUAL GROWTH CONFERENCE - ENTERA BIO LTDEarnings Call TranscriptsHi, everyone. I'm Gary Nachman, a senior biotech biopharma analyst at Canaccord Genuity, and we're very excited to have Miranda Toledano, CEO of Interra Bio, with us to discuss some recent exciting developments at the co
- 3mo agoENTXCG 46TH ANNUAL GROWTH CONFERENCE - ENTERA BIO LTDEarnings Call TranscriptsHi, everyone. I'm Gary Nachman, a senior biotech biopharma analyst at Canaccord Genuity, and we're very excited to have Miranda Toledano, CEO of Interra Bio, with us to discuss some recent exciting developments at the co
- 3mo agoENTXEntera Announces Second Quarter 2026 Financial Results and Business UpdatesGlobeNewswireU.S. Food and Drug Administration (FDA) Alignment on 12-Month Registrational Phase 3 Study to Support NDA for EB613 - the First Oral Anabolic Tablet in Development for Postmenopausal Women with Osteoporosis
- 3mo agoENTXEntera Bio Phase 2 Data Supporting EB613’s (Oral PTH(1-34)) Anabolic Effect on Postmenopausal Women with Osteoporosis at High Risk for Fracture Selected for Plenary Poster Session Presentation at the ASBMR 2026 Annual MeetingGlobeNewswireTEL AVIV, Aug. 04, 2026 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ:ENTX) ("Entera" or the "Company"), a leader in the development of oral peptides, today announced that post-hoc data from its Phase 2
- 3mo agoENTXEntera Bio to Participate in the Canaccord Genuity 46th Annual Growth ConferenceGlobeNewswireTEL AVIV, July 31, 2026 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ:ENTX) ("Entera" or the "Company"), a leader in the development of oral peptides, today announced that the Company’s Chief Executive
- 3mo agoENTXGreenberg Traurig Advises Entera Bio in Record $275M Israeli Biotech PIPEPR NewswireGlobal law firm Greenberg Traurig, P.A. advised Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of oral peptides, in connection with its...
- 3mo agoENTXEntera Bio Announces Pricing of Oversubscribed $275 Million Private PlacementGlobeNewswireThe offering is led by existing investor BVF Partners L.P. Expected gross proceeds are anticipated to extend the Company's cash runway into 2030 and fully support Phase 3 registrational studies for EB613, the first
- 4mo agoENTXPositive FDA Feedback on Phase 3 Brings Entera Bio's Oral Osteoporosis Pill One Step Closer to MarketGlobeNewswireEntera Bio (NASDAQ:ENTX) may have just cleared its biggest regulatory hurdle yet. The FDA has provided positive feedback on the Phase 3 protocol for EB613, the company's oral osteoporosis tablet, creating a clear
- 4mo agoENTXEntera Bio Receives Positive FDA Feedback on 12-Month Registrational Phase 3 Study for EB613 - the First Oral Anabolic Tablet in Development for Postmenopausal Women with OsteoporosisGlobeNewswireThe planned Phase 3 trial in approximately 750 postmenopausal women with osteoporosis, with a primary endpoint of total hip bone mineral density (BMD) at Month 12, would support Entera’s plan to submit a New Drug
- 4mo agoENTXOPKEntera Reports Robust Preclinical Data for EB612 (Oral LA-PTH(1-34)) for Hypoparathyroidism and EB618 (Oral GLP-1/Glucagon) for Obesity at ENDO 2026GlobeNewswireEB612, a first-in-class long-acting PTH(1-34) oral peptide for hypoparathyroidism, produced robust bioavailability and sustained increases in calcium across three preclinical models; IND is expected in late 2026 EB618,
- 4mo agoENTXENDO 2026 Oral Presentation Highlights Comparative Clinical Data for Entera's Breakthrough Single Tablet EB613 (First-in-Class Oral PTH(1-34) Anabolic for Osteoporosis)GlobeNewswireThe pharmacokinetic (PK) and pharmacodynamic (PD) profiles of single tablet EB613, multi-tablet EB613 and Forteo® reported for the first time as an oral presentation at ENDO 2026 Single tablet EB613 achieved a
- 5mo agoENTXEntera's EB613, First-in-Class Oral PTH(1-34) Anabolic for Osteoporosis - Single Tablet Data Selected for Late Breaking Oral Presentation at ENDO 2026 Annual Meeting; Additional Oral Peptide Pipeline Data Accepted for PresentationGlobeNewswireTEL AVIV, May 28, 2026 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ:ENTX) ("Entera" or the "Company"), a leader in the development of oral peptides, today announced that multiple abstracts across its oral peptide
- 6mo agoENTXEntera Announces First Quarter 2026 Financial Results and Updates Across its Oral Peptide ProgramsGlobeNewswireEB613, the first oral anabolic (bone building) peptide tablet for postmenopausal women with osteoporosis – Phase 3 protocol submitted with FDA feedback expected imminently; incremental data submitted to ENDO2026 and
- 6mo agoENTXBriefCast Publishes Transcript: Entera Bio's Osteoporosis KOL Roundtable on EB613 - Oral Anabolic Tablet OpportunityGlobeNewswireIn a virtual Key Opinion Leader (KOL) roundtable hosted today, Entera Bio (NASDAQ:ENTX) convened globally recognized authorities in osteoporosis and women's health to discuss the current osteoporosis treatment
- 7mo agoENTXEntera Bio to Host Key Opinion Leader Webinar Highlighting the Osteoporosis Treatment Landscape and the Opportunity for EB613GlobeNewswireTEL AVIV, Israel, April 14, 2026 (GLOBE NEWSWIRE) -- TEL AVIV, Israel, April 14, 2026 -- Entera Bio Ltd. (NASDAQ:ENTX) ("Entera" or the "Company"), a leader in the development of oral peptides, today announced it will
- 7mo agoENTXGreenberg Traurig Represents Israel-based Entera Bio in $10M Private Placement Led by BVF PartnersPR NewswireGlobal law firm Greenberg Traurig, P.A. advised Israel-based Entera Bio Ltd. (Nasdaq: ENTX), a clinical-stage biotechnology company focused on the...
- 7mo agoENTXEntera Bio Announces Pricing of $10.0 Million Direct Investment by BVF Partners with Potential for up to $24.5 Million in Total ProceedsGlobeNewswireTEL AVIV, Israel, April 02, 2026 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ:ENTX) ("Entera" or the "Company"), a leader in the development of oral peptides, today announced that it has entered into a securities
- 7mo agoENTXEntera Bio Announces Full Year 2025 Financial Results and Provides Business UpdatesGlobeNewswireEB613, the first oral anabolic (bone building) peptide tablet for postmenopausal women with osteoporosis – FDA Type A endpoint alignment in July 2025, Phase 3 protocol submitted to the FDA with comments expected in early
- 8mo agoENTXEntera Bio Submits Streamlined Phase 3 Protocol to Initiate Registrational Program for EB613 in Postmenopausal Women with OsteoporosisGlobeNewswirePhase 3 study designed with total hip BMD primary endpoint assessed at 12 months, rather than at 24 months EB613 single tablet final commercial formulation (Next-Gen EB613) replaces multi-tablet EB613 as Phase 3
- 8mo agoENTXEntera Bio to Participate in the Leerink Partners 2026 Global Healthcare ConferenceGlobeNewswireTEL AVIV, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ:ENTX) ("Entera" or the "Company"), a leader in the development of oral peptide and protein replacement therapies, today announced that
- 9mo agoENTXEntera Bio Announces Open Market Purchases of Company Stock by Board MembersGlobeNewswireTEL AVIV, Feb. 11, 2026 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ:ENTX) ("Entera" or the "Company"), a leader in the development of oral peptide and protein replacement therapies, today announced that
- 9mo agoENTXEntera Bio Appoints Former Pfizer Executive Geno J. Germano as Chairman of the Board Ahead of Key MilestonesGlobeNewswireTEL AVIV, Feb. 09, 2026 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ:ENTX) ("Entera" or the "Company"), a leader in the development of oral peptide and protein replacement therapies, today announced that
- 9mo agoENTXOPKOPKO Health and Entera Bio Expand Partnership to Advance First-in-Class Oral Long Acting PTH Tablet for Patients with HypoparathyroidismGlobeNewswireThis is the third program that successfully combines Entera's oral peptide N-Tab® platform with OPKO's advanced protein chemistry capabilities The companies have accelerated this program and aim to file an
- 9mo agoENTXEntera Bio Announces Upcoming Q1 2026 Corporate Priorities and Pipeline OutlookGlobeNewswireFinal EB613 Phase 3 Protocol Submission to FDA Planned for Q1 2026, Following December 19th 2025 FDA Ruling Next-Generation EB613 Phase 1 Bridging Study Progressing with Results Expected During Q1 2026
- 10mo agoENTXEntera Bio Congratulates the FNIH-ASBMR-SABRE Team on FDA's Qualification of Total Hip BMD as Regulatory Endpoint: Huge Win for Osteoporosis InnovationGlobeNewswireFDA qualification of Total Hip BMD as a validated surrogate endpoint for novel osteoporosis drug development further bolsters Entera's July 2025 FDA alignment and regulatory strategy for EB613 Underscores
- 10mo agoENTXEntera Bio Announces New Data Supporting Further Development of a Proprietary First-in-Class Oral, Long-Acting PTH Tablet for Patients with Hypoparathyroidism (EB612 Program)GlobeNewswireJERUSALEM, Dec. 22, 2025 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ:ENTX) ("Entera" or the "Company"), a leader in the development of oral peptides and proteins replacement therapies, today announced new validating in
- 11mo agoENTXEntera Bio to Participate in the 8th Annual Evercore ISI Healthcare ConferenceGlobeNewswireJERUSALEM, Nov. 18, 2025 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ:ENTX), ("Entera" or the "Company") a leader in the development of oral peptide and protein replacement therapies, today announced that the Company's
- 12mo agoENTXEntera Bio Announces Third Quarter 2025 Financial Results and Business UpdatesGlobeNewswireFDA Agreement on BMD as Primary Endpoint for EB613 Registrational, Phase 3 Study EB613 Phase 2 Data Demonstrating Consistent Efficacy across Younger Post-Menopausal Women with Osteoporosis and its Impact on Trabecular
- 1y agoENTXEntera Bio Presents Positive New Clinical Data from EB613 Phase 2 Trial Demonstrating Significant Bone Density Improvements in Early Postmenopausal WomenGlobeNewswireConsistency of BMD gains presented at NAMS 2025 demonstrate EB613's efficacy in both young postmenopausal women and in women 10 years post-menopause Data further support EB613 potential as a first-in-class oral
- 1y agoENTXEntera Bio to Present New Clinical Data from Phase 2 Trial of EB613 at the 2025 North American Menopause Society (NAMS) Annual MeetingGlobeNewswireJERUSALEM, Oct. 16, 2025 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ:ENTX), a leader in the development of oral peptide and protein replacement therapies, today announced that it will present new clinical data from its
- 1y agoENTXEntera Bio Reports Positive PK Data for First-in-Class Oral GLP-2 Tablet Treatment for Patients with Short Bowel Syndrome at the 2025 ESPEN CongressGlobeNewswirePreclinical Data for OPK-8801003 Demonstrate Substantially Longer Biological Half-Life with Peak Plasma Levels Comparable to Gattex®, the Only Approved GLP-2 Therapy Oral GLP-2 Tablet Could Transform Treatment
- 1y agoENTXEntera Bio Presents Positive Effects of EB613 on Both Trabecular and Cortical Bone in Postmenopausal Women with Osteoporosis at ASBMR 2025GlobeNewswireEB613 Demonstrates Significant Effects on Both Trabecular and Cortical Bone Compartments After Just 6 Months of Treatment in Phase 2 Study; Cortical Improvements Comparable to Injectable Teriparatide and Abaloparatide
- 1y agoENTXEntera Bio to Unveil Clinical and Non-Clinical Data Across 3 Oral Peptide Programs at Upcoming September ConferencesGlobeNewswireOsteoporosis Program: Phase 2 analysis exploring the dual actions of oral PTH(1-34) tablet treatment, EB613 on trabecular and cortical bone, and Next-Gen EB613 PK/PD data slated for oral and poster presentations at
- 1y agoENTXEntera Bio Announces Second Quarter 2025 Financial Results and Business UpdatesGlobeNewswireFDA provides pivotal agreement on EB613 Phase 3 design, confirming Bone Mineral Density (BMD) as primary endpoint and clearing streamlined pathway for first oral anabolic osteoporosis treatmentSignificant regulatory and
- 1y agoENTXEntera Bio Receives FDA Agreement on BMD as Primary Endpoint for EB613 Registrational, Phase 3 Study in Post-Menopausal Women with OsteoporosisGlobeNewswireJERUSALEM, July 28, 2025 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ:ENTX), a leader in the development of oral peptides and protein replacement therapies, announced today that in a written response to a Type A meeting
- 1y agoENTXOPKOPKO Health and Entera Bio Announce Abstract on PK/PD of Oral GLP-2 Tablet for the Treatment of Short Bowel Syndrome Selected for 2025 ESPEN CongressGlobeNewswireMIAMI and JERUSALEM, July 08, 2025 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ:OPK) ("OPKO") and Entera Bio Ltd. (NASDAQ:ENTX) ("Entera") today announced that their abstract "First-in-Class Oral GLP-2 Analog for
- 1y agoENTXEntera Bio Data for EB613 Effects on Trabecular and Cortical Bone in Post-Menopausal Women with Osteoporosis Selected for Oral Presentation at ASBMR 2025 Annual MeetingGlobeNewswireJERUSALEM, June 26, 2025 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ:ENTX), a leader in the development of oral peptides and proteins replacement therapies, announced that new data exploring the dual actions of EB613
- 1y agoENTXOPKOPKO Health and Entera Bio Abstract for First-in-Class Dual GLP-1/Glucagon Tablet Candidate for Patients with Obesity and Metabolic Disorders Selected for Presentation at the ENDO 2025 Annual MeetingGlobeNewswireMIAMI and JERUSALEM, June 25, 2025 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ:OPK) and Entera Bio Ltd. (NASDAQ:ENTX) ("Entera") today announced that new pharmacologic and pharmacokinetic in vivo data for
- 1y agoENTXEntera Bio Announces First Quarter 2025 Financial Results and Business UpdatesGlobeNewswireJERUSALEM, May 09, 2025 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ:ENTX), a leader in the development of oral peptide and protein replacement therapies, today reported financial results and key business updates for
- 1y agoENTXEntera Bio's EB613 Demonstrates Early Impact on Both Trabecular and Cortical Bone Compartments with 6 Months of Treatment in Post-Menopausal Women with Osteoporosis - Highlighted as Oral Presentation at WCO-IOF ESCEOGlobeNewswireJERUSALEM, April 15, 2025 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ:ENTX), a leader in the development of oral peptides and proteins replacement therapies, announced highlights from Dr. Rachel B Wagman's oral
- 1y agoENTXEntera Bio Announces Full Year 2024 Financial Results and Provides Business UpdatesGlobeNewswireJERUSALEM, March 28, 2025 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ:ENTX), a leader in the development of oral peptides and proteins replacement therapies, today reported financial results and key business